180 related articles for article (PubMed ID: 26262905)
1. Adverse Events in Very Young Children Prescribed Psychotropic Medications: Preliminary Findings from an Acute Clinical Sample.
Lee CS; Williamson LR; Martin SE; DeMarco M; Majczak M; Martini J; Hunter HL; Fritz G; Boekamp J
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):509-13. PubMed ID: 26262905
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic medication use in children and adolescents in an inpatient setting.
Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V
Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844
[TBL] [Abstract][Full Text] [Related]
3. Novel psychotropic medications in children: new toxicities to master.
Jacobs ES; Dickstein DP; Liebelt EL
Pediatr Emerg Care; 2001 Jun; 17(3):226-31. PubMed ID: 11437154
[No Abstract] [Full Text] [Related]
4. Psychotropic medication use in pediatric patients with cancer.
Pao M; Ballard ED; Rosenstein DL; Wiener L; Wayne AS
Arch Pediatr Adolesc Med; 2006 Aug; 160(8):818-22. PubMed ID: 16894081
[TBL] [Abstract][Full Text] [Related]
5. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists.
Efron D; Hiscock H; Sewell JR; Cranswick NE; Vance AL; Tyl Y; Luk ES
Pediatrics; 2003 Feb; 111(2):372-5. PubMed ID: 12563066
[TBL] [Abstract][Full Text] [Related]
6. Medication prescribing practices in a child and adolescent psychiatry outpatient clinic.
Aras S; Varol Tas F; Unlu G
Child Care Health Dev; 2007 Jul; 33(4):482-90. PubMed ID: 17584405
[TBL] [Abstract][Full Text] [Related]
7. Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population.
Radigan M; Lannon P; Roohan P; Gesten F
J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):44-56. PubMed ID: 15741785
[TBL] [Abstract][Full Text] [Related]
8. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
9. Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey.
Coleman DM; Adams JB; Anderson AL; Frye RE
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):107-123. PubMed ID: 30724573
[TBL] [Abstract][Full Text] [Related]
10. How young is too young for psychotropic medication?
McGuinness TM
J Psychosoc Nurs Ment Health Serv; 2007 Jun; 45(6):20-3. PubMed ID: 17601156
[TBL] [Abstract][Full Text] [Related]
11. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
[TBL] [Abstract][Full Text] [Related]
12. Psychotropic drug effects contributing to psychiatric hospitalization of children: a preliminary study.
Fialkov MJ; Hasley S
J Dev Behav Pediatr; 1984 Dec; 5(6):325-30. PubMed ID: 6511930
[TBL] [Abstract][Full Text] [Related]
13. Trends of prescription psychotropic medication exposures in pediatric patients, 2009-2018.
Hunter K; Poel K; Pennington S; Bindseil I; Banerji S; Leonard J; Wang GS
Clin Toxicol (Phila); 2022 Feb; 60(2):243-251. PubMed ID: 34196239
[TBL] [Abstract][Full Text] [Related]
14. Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials.
Shurtz L; Schwartz C; DiStefano C; McPartland JC; Levin AR; Dawson G; Kleinhans NM; Faja S; Webb SJ; Shic F; Naples AJ; Seow H; Bernier RA; Chawarska K; Sugar CA; Dziura J; Senturk D; Santhosh M; Jeste SS
Autism; 2023 May; 27(4):952-966. PubMed ID: 36086805
[TBL] [Abstract][Full Text] [Related]
15. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
16. Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews.
Golder S; Medaglio D; O'Connor K; Hennessy S; Gross R; Gonzalez Hernandez G
JAMA Netw Open; 2023 Jul; 6(7):e2323746. PubMed ID: 37459097
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty.
Karanges EA; Stephenson CP; McGregor IS
Aust N Z J Psychiatry; 2014 Oct; 48(10):917-31. PubMed ID: 24927734
[TBL] [Abstract][Full Text] [Related]
18. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors.
Rushton JL; Clark SJ; Freed GL
Pediatrics; 2000 Jun; 105(6):E82. PubMed ID: 10835095
[TBL] [Abstract][Full Text] [Related]
19. Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures.
Bolton JM; Morin SN; Majumdar SR; Sareen J; Lix LM; Johansson H; Odén A; McCloskey EV; Kanis JA; Leslie WD
JAMA Psychiatry; 2017 Jun; 74(6):641-648. PubMed ID: 28423154
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of pervasive developmental disorders in children and adolescents.
Masi G
CNS Drugs; 2004; 18(14):1031-52. PubMed ID: 15584771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
